Improved Antimalaria Drug

  • ChemPubSoc Europe Logo
  • Author: Chemistry – A European Journal
  • Published Date: 12 July 2018
  • Source / Publisher: Chemistry – A European Journal/Wiley-VCH
  • Copyright: Wiley-VCH Verlag GmbH & Co. KGaA
thumbnail image: Improved Antimalaria Drug

Related Societies

Malaria and tuberculosis are health problems which are especially common in developing countries A major roadblock to the eradication of such diseases is their resistance to currently available drugs. Repurposing existing drugs in the form of new derivatives is one approach to solve this problem. An example of this is the organo-iron derivative of the antimalarial drug chloroquine, ferroquine, which is now in the clinical trial phase.


Peter Sadler, Prinessa Chellan, University of Warwick, UK, and colleagues have investigated if the organometallic derivatization of sulfadoxine, a drug used to treat malaria and other microbial diseases, could enhance its activity. The researchers screened the effectiveness of arene-ruthenium(II), cyclopentadienyl-iridium(III), and cyclopentadienyl-rhodium(III) derivatives of sulfadoxine against various microbes, including Plasmodium falciparum, the malaria strain that infects humans, and Mycobacterium tuberculosis.


Sulfadoxine itself has little activity against these pathogens. However, the organo-Rh and organo-Ir complexes were good inhibitors, effectively "switching on" the activity of sulfadoxine (pictured). Notably, some metallo-sulfadoxines were active against late-stage gametocytes (LSG) of the malaria parasites, whereas the drugs sulfadoxine, pyrimethamine, and chloroquine were not. This is a significant finding because LSGs cause the spread of the disease by transfer from a human host to female Anopheles mosquitos, which can then infect another person.


 

Article Views: 1223

Sign in Area

Please sign in below

Additional Sign In options

Please note that to comment on an article you must be registered and logged in.
Registration is for free, you may already be registered to receive, e.g., the newsletter. When you register on this website, please ensure you view our terms and conditions. All comments are subject to moderation.

Article Comments - To add a comment please sign in

Bookmark and Share

If you would like to reuse any content, in print or online, from ChemistryViews.org, please contact us first for permission. more


CONNECT:

ChemistryViews.org on Facebook

ChemistryViews.org on Twitter ChemistryViews.org on YouTube ChemistryViews.org on LinkedIn Sign up for our free newsletter


A product of ChemPubSoc Europe (16 European Chemical Societies)and Wiley-VCH